Medtronic Allocates $90M to Anteris in Strategic TAVR Investment
Medtronic invested $90 million in Anteris through private purchase of 15.65 million shares at $5.75 each, alongside Anteris’s $230 million public offering. The stake gives Medtronic equity exposure to Anteris’s DurAVR® Transcatheter Heart Valve and supports the global PARADIGM trial execution and future TAVR commercialization.
Related News
AMD
AMD Pledges $10B Taiwan Investment for 2.5D EFB Packaging and Ramps 2nm “Venice” CPUs
AMD•
WMT
Walmart Set for Q1 EPS of $0.66 on $175B Revenue; Value Outlook Tempered
WMT•
TNL
Travel + Leisure Co. Declares $0.60 Per Share Cash Dividend Payable June 30
TNL•
GOOGL
Alphabet Executes Record Yen Bond Sale as Google Secures 9.7 GWh AI Storage Contracts
GOOGL•
NVDA
Nvidia posts $81.6bn Q1 revenue, raises dividend 25-fold and authorizes $80bn buyback
NVDA•
Sources
YGGG